US Bancorp DE bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,375 shares of the company’s stock, valued at approximately $80,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. First Horizon Advisors Inc. acquired a new position in Tempus AI in the third quarter valued at about $30,000. FNY Investment Advisers LLC bought a new position in Tempus AI in the 4th quarter valued at about $67,000. IFP Advisors Inc acquired a new position in shares of Tempus AI in the 4th quarter valued at approximately $76,000. Stifel Financial Corp acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $218,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tempus AI during the 4th quarter worth approximately $178,000. Institutional investors and hedge funds own 24.22% of the company’s stock.
Insider Activity
In other news, major shareholder Bradley A. Keywell sold 170,720 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $35.45, for a total value of $6,052,024.00. Following the sale, the insider now directly owns 15,993,729 shares of the company’s stock, valued at approximately $566,977,693.05. This represents a 1.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Nadja West sold 809 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total transaction of $41,347.99. Following the sale, the director now owns 37,705 shares of the company’s stock, valued at approximately $1,927,102.55. This trade represents a 2.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,749,469 shares of company stock valued at $322,529,733.
Tempus AI Price Performance
Analyst Ratings Changes
Several research analysts have commented on TEM shares. Guggenheim restated a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Needham & Company LLC boosted their price target on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Bank of America raised their price objective on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Piper Sandler lowered their target price on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, Wolfe Research cut shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and an average target price of $61.18.
Read Our Latest Report on Tempus AI
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- What to Know About Investing in Penny Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Options Trading – Understanding Strike Price
- The “Quality” Rotation: Back to Basics Investing
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.